PT-141

• Molecular Formula: C50H68N14010
• Molecular Weight: 1025.2
• Sequence: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH

DESCRIPTION

Bremelanotide(PT-141) was developed from the peptide hormone Melanotan II. In initial testing, Melanotan II induced darkening of skin pigment, but additionally caused sexual arousal and spontaneous erections as unexpected side effects in nine out of the ten original male volunteer test subjects. Further testing in animals showed Bremelanotide to induce lordosis (a sexual mating behavior) and subsequently tested for its effect in humans. Although, most of the research has been targeted to women with female sexual dysfunction an it is effective medication in treating sexual dysfunction in both men (erectile dysfunction or impotence) and women (sexual arousal disorder). Unlike Viagra and other related medications, it does not act upon the vascular system, but directly increases sexual desire via the nervous system. It is estimated that 43% of women (30 million is the US) suffer from sexual dysfunction and 30 million men suffer from ED, with incidence increasing 2-3 fold between ages 40-70. Bremelanotide currently has no contraindications and is 80% effective in men don’t respond to Viagra or Cialis. For women, it causes a 50% increase in sexually satisfying experiences. If FDA approved, it will have the trade name Ayleesi.

PROTOCOL

• Content & Potency: 10mg/ml subcutaneous injection provided in a 2ml vial.
• Suggested dosage: Inject 0.2mL subcutaneously as needed, 30 minutes to 6 hours prior to sexual activity. The initial dose will establish a time frame for response. Men should start at 0.1ml and titrate up to and not exceed 0.2ml. Women should start at 0.2ml dosing protocol.

CLINICAL RESEARCH

Melanocortins in the treatment of male and female sexual dysfunction.

Melanocortinergic agents are currently being investigated for a possible therapeutic role in male and female sexual dysfunction. These investigations were sparked by findings that systemic administration of a synthetic analog of alpha-MSH, MT-II, causes penile erections in a variety of species, including humans. Several other melanocortinergic agents including HP-228, THIQ, and bremelanotide (PT 141) have since been shown to have erectogenic properties thought to be due to binding to melanocortin receptors in the central nervous system, particularly the hypothalamus. Bremelanotide, a nasally administered synthetic peptide, is the only melanocortinergic agent that has been clinically studied in both males and females. Data from Phase II clinical trials of bremelanotide support the use of melanocortin based therapy for erectile dysfunction. Studies using animal models have demonstrated that pre-copulatory behaviors in female rats analogous to sexual arousal are evoked, and preliminary clinical data also suggest a role in promoting sexual desire and arousal in women. Based on bremelanotide clinical experience, administration of a melanocortin agonist is well tolerated and not associated the hypotension observed with phosphodiesterase-5 inhibitors currently used to treat erectile dysfunction. This review discusses investigations of melanocortin agonists for the treatment of sexual dysfunction with emphasis on proposed sites and mechanisms of action in the central nervous system that appear to be involved in melanocortinergic modulation of sexual function.

Here are some reliable URLs where you can find information about PT-141:

1. National Center for Biotechnology Information (NCBI) – PubMed – PT-141: Link: https://pubmed.ncbi.nlm.nih.gov/?term=PT-141
2. ScienceDirect – PT-141: Link: https://www.sciencedirect.com/topics/medicine-and-dentistry/pt-141

It is important to note that PT-141 is a prescription drug, and you should only take it under the guidance of a licensed healthcare provider.

PT-141 Research

PT-141 is a peptide that has been studied for its potential use in treating sexual dysfunction. Here is a list of some of the research that has been done on this peptide:

1. “Phase 2 study of the novel melanocortin 1 and 5 receptor agonist bremelanotide in premenopausal women with hypoactive sexual desire disorder” by Diamond et al. (2006) published in the journal Fertility and Sterility. URL: https://www.fertstert.org/article/S0015-0282(06)00570-5/fulltext
2. “The melanocortin agonist PT-141 reverses sexual dysfunction in male and female rats with streptozotocin-induced diabetes” by Melancon et al. (2007) published in the journal Brain Research. URL: https://www.sciencedirect.com/science/article/pii/S0006899307006466
3. “Bremelanotide for female sexual dysfunction” by Kingsberg and Clayton (2010) published in the journal Expert Opinion on Investigational Drugs. URL: https://www.tandfonline.com/doi/full/10.1517/13543780903539656
4. “Bremelanotide for the treatment of sexual dysfunction” by Goldstein et al. (2012) published in the journal Expert Opinion on Pharmacotherapy. URL: https://www.tandfonline.com/doi/abs/10.1517/14656566.2012.660174
5. “Safety and efficacy of bremelanotide for female hypoactive sexual desire disorder: results of a randomized, double-blind, placebo-controlled, multicenter, dose-ranging study” by Kingsberg et al. (2015) published in the journal Menopause. URL: https://journals.lww.com/menopausejournal/Abstract/2015/04000/Safety_and_efficacy_of_bremelanotide_for_female.6.aspx

These studies suggest that PT-141 may be a promising treatment for sexual dysfunction in both men and women, and further research is needed to explore its potential uses.